Singapore, December 30, 2020 – Credo Diagnostics Biomedical Pte. Ltd., the leader of point-of-care rapid molecular diagnostic, announced today it has completed internal analysis and confirmed that all its VitaPCR™ SARS-CoV-2 related assays – including the VitaPCR™ SARS-CoV-2 Assay, the VitaPCR™ SARS-CoV-2 Gen 2 Assay, and the Influenza A&B/SARS-CoV-2 Assay – can successfully detect the newly discovered variant strain of SARS-CoV-2.
On December 14, 2020, authorities of the United Kingdom of Great Britain and Northern Ireland reported that a new SARS-CoV-2 variant was identified through viral genomic sequencing. Referred to as SARS-CoV-2 VUI 202012/01, the new variant is defined by multiple spike protein mutations; preliminary modelling data indicates that the variant may spread more readily between people.
“It is well known and expected that viruses in general, and SARS-CoV-2 in particular, constantly change through mutation leading to the emergence of new variants” said Dr. Winston Wong Jr., Chairman of Credo Diagnostics Biomedical. “It is particularly important for us to assure that all our assays can properly detect any variant of the SARS-CoV-2. We are following up closely with the WHO and the CDC to continue to study and track emerging variants of the virus”.
Following in-depth BLASTN analysis against the spike gene mutation sequences of the SARS-CoV-2 VUI 202012/01, all VitaPCR™ SARS-CoV-2 related assays were confirmed to successfully detect the new variant strain of SARS-CoV-2.
About Credo Diagnostics Biomedical Pte. Ltd.
Credo Diagnostics develops and manufactures innovative, easy-to-use and rapid molecular diagnostic solutions for Point-of-Care (POC) applications at affordable costs without compromising accuracy and speed in the areas Human Health. Leveraging solid and established science, combined with efficient integration and strategic innovation, Credo Diagnostics Biomedical provides advanced medical technologies for all.